ScholarIQanswers from OpenAlex
Pembrolizumab for Early Triple-Negative Breast Cancer
PaperCitations, authors & open-access status
Pembrolizumab for Early Triple-Negative Breast Cancer is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Pembrolizumab for Early Triple-Negative Breast Cancer have?
ScholarIQcitation count
Pembrolizumab for Early Triple-Negative Breast Cancer has 3,189 citations in the OpenAlex counts ScholarIQ stores.
When was Pembrolizumab for Early Triple-Negative Breast Cancer published?
ScholarIQyear
Pembrolizumab for Early Triple-Negative Breast Cancer has 2020 year in the ScholarIQ index.
What is the open-access status of Pembrolizumab for Early Triple-Negative Breast Cancer?
ScholarIQoa status
Pembrolizumab for Early Triple-Negative Breast Cancer has bronze oa status in the ScholarIQ index.
What is the DOI of Pembrolizumab for Early Triple-Negative Breast Cancer?
ScholarIQdoi
The DOI for Pembrolizumab for Early Triple-Negative Breast Cancer is on the source record.
What is the PMID of Pembrolizumab for Early Triple-Negative Breast Cancer?
ScholarIQpmid
The PMID for Pembrolizumab for Early Triple-Negative Breast Cancer is on the source record.
What is the OpenAlex record for Pembrolizumab for Early Triple-Negative Breast Cancer?
ScholarIQopenalex
The OpenAlex for Pembrolizumab for Early Triple-Negative Breast Cancer is on the source record.